MedTrace Logo

What Are the Effects of a Bilateral Hip Exoskeleton During Daily Use by 65+ Adults?

NCT06041100 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2024-02-01

No results posted yet for this study

Summary

Despite the huge popularity exoskeletons have gained in the past years and the benefits that they have shown to provide to users, there are still many aspects of wearing an exoskeleton that have yet to be determined. Therefore, the main objective of this study is to evaluate the feasibility using the acceptability of incorporating a passive assistive bilateral exoskeleton into the daily routine of pre-frail adults for a duration of 12-weeks. The second aim of the study is to determine whether this effect can be sustained even after a period of 6-weeks following the cessation of usage.

Conditions

  • Pre-frail Senior Adults

Interventions

DEVICE

Exoskeleton

Use a passive assistive hip exoskeleton (alQ, Imasen Electrical Industrial Co., Ltd.) for 30 minutes daily during moderate to intensive activities over a period of 12-weeks. The exoskeleton is designed to aid hip flexion and as such its primary role is to improve gait by increasing step length and improving speed. The amount of time the exoskeleton has been used will be weekly monitored through phone calls and two gait sessions will be conducted to measure the development.

Sponsors & Collaborators

  • Imasen Electrical Industrial Co., Ltd.

    collaborator UNKNOWN

  • Aalborg Municipality

    collaborator OTHER

  • Aalborg University

    lead OTHER

Principal Investigators

  • Cristina-Ioana Pirscoveanu · Aalborg University

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
65 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-09-06
Primary Completion
2024-01-30
Completion
2024-01-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06041100 on ClinicalTrials.gov